ATYPICAL/MALIGNANT MENINGIOMA

Clinical trials for ATYPICAL/MALIGNANT MENINGIOMA explained in plain language.

Never miss a new study

Get alerted when new ATYPICAL/MALIGNANT MENINGIOMA trials appear

Sign up with your email to follow new studies for ATYPICAL/MALIGNANT MENINGIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Can an immune booster fight rare brain tumors?

Disease control Terminated

This phase 2 trial tests whether the immunotherapy drug nivolumab can shrink tumors or slow their growth in adults with rare central nervous system (brain or spine) tumors that have returned after prior treatment. Participants receive nivolumab by IV every 2 to 4 weeks for up to …

Matched conditions: ATYPICAL/MALIGNANT MENINGIOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Aug 19, 2026 10:00 UTC

ATYPICAL/MALIGNANT MENINGIOMA

Get alerted when new ATYPICAL/MALIGNANT MENINGIOMA trials appear

Can an immune booster fight rare brain tumors?